Identification of a novel DNA repair-related prognostic signature predicting survival of patients with hepatocellular carcinoma

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-229307467
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortettieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Venook AP, Papandreou C, Furuse J, Guevara LLD. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;Suppl 15(Supplement 4):5–13. doi:10.1634/theoncologist.2010-S4-05
   Google Scholar
• Goh GB, Chang PE, Tan CK. Changing epidemiology of hepatocellular carcinoma in Asia. Best Pract Res Clin Gastroenterol. 2015;29(6):919–928. doi:10.1016/j.bpg.2015.09.00726651253
   PubMed Web of Science ®Google Scholar
• Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2010;47(3):897–907. doi:10.1002/hep.22160
   Web of Science ®Google Scholar
• Wang NY, Wang C, Li W, et al. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev. 2014;15(4):1539–1544. doi:10.7314/apjcp.2014.15.4.153924641364
   PubMedGoogle Scholar
• Wang L, Yao M, Pan LH, Qian Q, Yao DF. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatob Pancreat Dis Int. 2015;14(4):361–366. doi:10.1016/S1499-3872(15)60396-4
   PubMed Web of Science ®Google Scholar
• Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110. doi:10.1053/j.gastro.2009.04.00519362088
   PubMed Web of Science ®Google Scholar
• Sun DW, Zhang YY, Sun XD, et al. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis. Clinica Chimica Acta. 2015;448:161–169. doi:10.1016/j.cca.2015.06.027
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31(4):302–308.11129271
   PubMed Web of Science ®Google Scholar
• Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer. 2015;4(1):39–50. doi:10.1159/00036772726020028
   PubMed Web of Science ®Google Scholar
• Dalerba P, Sahoo D, Paik S, et al. CDX2 as a prognostic biomarker in Stage II and Stage III colon cancer. N Engl J Med. 2016;374(3):211–222. doi:10.1056/NEJMoa150659726789870
   PubMed Web of Science ®Google Scholar
• Jin GZ, Yu WL, Dong H, et al. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma. J Hepatol. 2013;59(3):510–517. doi:10.1016/j.jhep.2013.04.02823665285
   PubMed Web of Science ®Google Scholar
• Cheng W, Ren X, Zhang C, et al. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–2234. doi:10.1212/WNL.000000000000277027225222
   PubMed Web of Science ®Google Scholar
• Zhao L, Jiang L, He L, et al. Identification of a novel cell cycle-related gene signature predicting survival in patients with gastric cancer. Journal of Cellular Physiology May 2019;234(5):6350–6360.
   Google Scholar
• Lourdes M, Moisès B, María José R, et al. Gene expression signature in urine for diagnosing and assessing aggressiveness of bladder urothelial carcinoma. Clin Cancer Res. 2010;16(9):2624–2633. doi:10.1158/1078-0432.CCR-09-337320406841
   PubMed Web of Science ®Google Scholar
• Sun T, Iris S, Victor M, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut. 2013;62(4):540–549. doi:10.1136/gutjnl-2012-30242322798500
   PubMed Web of Science ®Google Scholar
• Li Q, Su YL, Shen WX. A novel prognostic signature of seven genes for the prediction in patients with thymoma. J Cancer Res Clin Oncol. 2019;145(1):109–116. doi:10.1007/s00432-018-2770-x30328513
   PubMed Web of Science ®Google Scholar
• Villanueva A, Portela A, Sayols S, et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61(6):1945–1956. doi:10.1002/hep.2773225645722
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–15550. doi:10.1073/pnas.050658010216199517
   PubMed Web of Science ®Google Scholar
• Jeng KS, Chang CF, Jeng WJ, Sheen IS, Jeng CJ. Heterogeneity of hepatocellular carcinoma contributes to cancer progression. Crit Rev Oncol Hematol. 2015;94(3):337–347. doi:10.1016/j.critrevonc.2015.01.00925680939
   PubMed Web of Science ®Google Scholar
• Lin DC, Mayakonda A, Dinh HQ, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017;77(9):2255–2265. doi:10.1158/0008-5472.CAN-16-282228302680
   PubMed Web of Science ®Google Scholar
• Trevisani F, D’Intino PE, Morsellilabate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–575.11394657
   PubMed Web of Science ®Google Scholar
• Zhou F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12(8):1175–1181. doi:10.3748/wjg.v12.i8.117516534867
   PubMed Web of Science ®Google Scholar
• Li Z, Rui JA, Wang SB, Chen SG, Qiang Q. LCSGJ-T classification, 6th or 5th edition TNM staging did not independently predict the long-term prognosis of HBV-related hepatocellular carcinoma after radical hepatectomy. J Surg Res. 2010;159(1):538–544. doi:10.1016/j.jss.2008.09.00419111323
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Poon RT, Abdalla EK, et al. Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. J Gastrointest Surg. 2004;8(7):794–805. doi:10.1016/j.gassur.2004.06.01315531232
   PubMed Web of Science ®Google Scholar
• Tan JT, Zhao C, Peng NF, et al. Association between age and overall survival of patients with hepatocellular carcinoma after hepatic resection. J Surg Oncol. 2016;114(8):966. doi:10.1002/jso.2443427633143
   PubMed Web of Science ®Google Scholar
• Tangkijvanich P, Mahachai V, Suwangool P, Yong P. Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. 世界胃肠病学杂志 (英文版). 2004;10(11):1547–1550.15162522
   PubMedGoogle Scholar
• Zhang M, Zhang C, Du W, Yang X, Chen Z. ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker. Clin Transl Oncol. 2016;18(8):776–781. doi:10.1007/s12094-015-1430-826527032
   PubMed Web of Science ®Google Scholar
• Ashley EA. The precision medicine initiative: a new national effort. JAMA. 2015;313(21):2119–2120. doi:10.1001/jama.2015.359525928209
   PubMed Web of Science ®Google Scholar
• Yu Y, Feng X, Cang S. A two-microRNA signature as a diagnostic and prognostic marker of pancreatic adenocarcinoma. Cancer Manag Res. 2018;10:1507–1515. doi:10.2147/CMAR.S15871229942152
   PubMed Web of Science ®Google Scholar
• Cheng W, Ren X, Cai J, et al. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget. 2015;6(30):29285–29295. doi:10.18632/oncotarget.497826320189
   PubMedGoogle Scholar
• Bao Z-S, Li M-Y, Wang J, et al. Prognostic Value of a Nine-Gene Signature in Glioma Patients Based on mRNA Expression Profiling. CNS Neuroscience & Therapeutics. 2014:20(2):112–118.
   Google Scholar
• Yuan GQ, Wei NL, Mu LY, et al. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. Cancer Biomark. 2017;20(4):443–452. doi:10.3233/CBM-17020528869437
   PubMed Web of Science ®Google Scholar
• Lord CJ, Alan A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287–294. doi:10.1038/nature1076022258607
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366–374. doi:10.1038/3507723211357144
   PubMed Web of Science ®Google Scholar
• Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology. 2003;193(1):3–34.14599765
   PubMed Web of Science ®Google Scholar
• Memisoglu A, Samson L. Base excision repair in yeast and mammals. Mutat Res. 2000;451(1):39–51. doi:10.1016/s0027-5107(00)00039-710915864
   PubMed Web of Science ®Google Scholar
• Sarlinova M, Majerova L, Matakova T, et al. Polymorphisms of DNA repair genes and lung cancer in chromium exposure. Adv Exp Med Biol. 2016;833:1–8.
   Web of Science ®Google Scholar
• Annika A, Honglin S, Christy W, et al. Polymorphisms in DNA repair genes and epithelial ovarian cancer risk. Int J Cancer. 2010;117(4):611–618.
   Google Scholar
• Mcwilliams RR, Bamlet WR, Cunningham JM, et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res. 2008;68(12):4928–4935. doi:10.1158/0008-5472.CAN-07-553918544627
   PubMed Web of Science ®Google Scholar
• Xi-Dai L, Dong Z, Chao W, et al. Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma. Epidemiology. 2013;24(5):671–681. doi:10.1097/EDE.0b013e31829d274423788213
   PubMed Web of Science ®Google Scholar
• Han M-E, Kim J-Y, Kim GH, Park SY, Kim YH, Oh S-O. SAC3D1: a novel prognostic marker in hepatocellular carcinoma. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-34129-9
   Google Scholar
• Zheng L, Dai H, Hegde ML, et al. Fen1 mutations that specifically disrupt its interaction with PCNA cause aneuploidy-associated cancer. Cell Res. 2011;21(7):1052–1067. doi:10.1038/cr.2011.3521383776
   PubMed Web of Science ®Google Scholar
• Yang ZM, Chen WW, Wang YF. Study on gene differential expressions of substance and energy metabolism in chronic superficial gastritis patients of pi deficiency syndrome and of pi-wei hygropyrexia syndrome. Chin J Integr Med. 2012;32(9):1180–1187.
   Google Scholar
• Olst ESV, Blijlevens M, Menezes RXD, Meulen‐Muileman IHVD, Smit EF, Beusechem VWV. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment. Mol Oncol. 2017;11(5):534–551. doi:10.1002/1878-0261.1205228296343
   PubMed Web of Science ®Google Scholar
• Spina C, Saccucci P, Cozzoli E, Bottini E, Gloriabottini F. A study of three polymorphic sites of ADA gene in colon cancer. Cancer Invest. 2010;28(10):989. doi:10.3109/07357907.2010.48350120590444
   PubMed Web of Science ®Google Scholar
• Veiga-Castelli LC, Silva JCRE, Meola J, et al. Genomic alterations detected by comparative genomic hybridization in ovarian endometriomas. Braz J Med Biol Res. 2010;43(8):799–805. doi:10.1590/S0100-879X201000750007220725696
   PubMed Web of Science ®Google Scholar
• Bolar NA, Golzio C, Živná M, et al. Heterozygous loss-of-function SEC61A1 mutations cause autosomal-dominant tubulo-interstitial and glomerulocystic kidney disease with anemia. Am J Hum Genet. 2016;99(1):174–187. doi:10.1016/j.ajhg.2016.05.02827392076
   PubMed Web of Science ®Google Scholar
• Alrahbeni T, Sartor F, Anderson J, Miedzybrodzka Z, Mccaig C, Müller B. Full UPF3B function is critical for neuronal differentiation of neural stem cells. Mol Brain. 2015;8(1):33. doi:10.1186/s13041-015-0122-126012578
   PubMedGoogle Scholar